Post-marketing Surveillance (Use Result Surveillance) With Refixia®
Post-marketing Surveillance (Use Result Surveillance) With Refixia®. A Multicentre, Non-interventional Post Marketing Surveillance of Safety and Effectiveness of Refixia® in Routine Clinical Care With Haemophilia B Patients in Japan.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Søborg, Denmark
- Novo Nordisk Investigational Site
-
-
-
-
-
Aichi, Japan, 466-8560
- Nagoya University Hospital_Blood Transfusion
-
Aomori, Japan, 030-8553
- Aomori Prefectural Central Hospital_Pediatrics
-
Chiba, Japan, 270-2296
- Matsudo City General Hospital_Pediatrics
-
Chiba, Japan, 286-8523
- Japan Red Cross Narita Hospital_Hematology and Oncology
-
Chiba-shi, Chiba, Japan, 260-8677
- Chiba University Hospital_Diabetes, Metabolism and Endocrinology
-
Hyōgo, Japan, 654-0047
- Hyogo prefectural kobe children's hospital Dept. of Haem and Onclogy
-
Ibaraki, Japan, 300-0395
- Tokyo Medical University Ibaraki Medical Center_Ibaraki
-
Ishikawa, Japan, 920-8530
- Ishikawa Prefectural Central Hospital_Haematology
-
Kanagawa, Japan, 216-8511
- St. Marianna University School of Medicine Hospital_Pediatrics
-
Kanagawa, Japan, 252-0375
- Kitasato University Hospital_Blood Transfusion
-
Kitakyusyu-shi, Fukuoka, Japan, 807 8555
- Hospital of the University of Occupational And Environmental Health Japan_Pediatrics
-
Maebashi-shi, Gunma, Japan, 371-8511
- Gunma University Hospital_Hematology
-
Naha-shi, Okinawa, Japan, 902-8511
- Naha City Hospital_Cardiovascular Medicine
-
Nara, Japan, 634-8522
- Nara Medical University Hospital_Pediatrics
-
Nishinomiya-shi, Hyogo, Japan, 663 8051
- The Hospital of Hyogo College of Medicine_Haematology
-
Saitama, Japan, 330-8777
- Saitama Children's Med Centre_Hematology-Oncology
-
Tokushima, Japan, 773-8502
- Tokushima Red Cross Hospital_Pediatrics
-
Tokushima, Japan, 770-8503
- Tokushima University Hospital_Pediatrics
-
Tokyo, Japan, 160-0023
- Tokyo Medical Univ. Hospital_Laboratory Medicine
-
Tokyo, Japan, 167-0035
- Ogikubo Hospital_Blood Coagulation
-
Yamagata, Japan, 992-0035
- Ishiyama Clinic
-
Yokohama-shi, Kanagawa, Japan, 241-0811
- St. Marianna Univ., Yokohama City Seibu HP, Pediatrics Dept,
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- The decision to initiate treatment with commercially available Refixia® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. At each site of this study, all patients will be registered consecutively from the first patient after the launch of Refixia® (consecutively registered system).
- Diagnosis of haemophilia B in males or females, no age limitation. Patients younger than 12 years old will continue to be registered for 3 years of recruitment period regardless of the target number of patients.
- New patients who have not been previously exposed to Refixia®. Also patients previously exposed to Refixia® in NN7999-3639, -3747, -3774, -3775 or -3895 clinical trial can be enrolled in this study. The patients who have participated in NN7999 -3774 or -3895 clinical trial can be enrolled in this study as continuous cases until 30-September-2024 (one year before planned end of study date).
Exclusion Criteria:
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Known or suspected hypersensitivity to study product or related products.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with haemophilia B
Both patients who have not previously been exposed to Refixia® and patients previously exposed to Refixia® in one of the clinical trials can be included.
|
Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Adverse Reactions (ARs)
Time Frame: From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Count of events
|
From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Serious Adverse Events (SAEs)
Time Frame: From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Count of events
|
From baseline (week 0) to end of study (up to 6 years and 10 months)
|
|
Number of Serious Adverse Reactions (SARs)
Time Frame: From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Count of events
|
From baseline (week 0) to end of study (up to 6 years and 10 months)
|
|
Number of bleeding episodes as assessed by annualised bleeding rate (ABR)
Time Frame: From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Count of bleeding episodes
|
From baseline (week 0) to end of study (up to 6 years and 10 months)
|
|
Number of treatment requiring bleeding episodes as assessed by ABR
Time Frame: From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Count of bleeding episodes
|
From baseline (week 0) to end of study (up to 6 years and 10 months)
|
|
Haemostatic response of Refixia® in treatment of bleeds
Time Frame: From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Haemostatic response is assessed as success/failure based on a four-point scale (excellent, good, moderate and poor) by counting excellent and good as success and moderate and poor as failure.
|
From baseline (week 0) to end of study (up to 6 years and 10 months)
|
|
Haemostatic response of Refixia® in treatment of bleeds in perioperative management during surgical procedures
Time Frame: From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Haemostatic response is assessed as success/failure based on a four-point scale (excellent, good, moderate and poor) by counting excellent and good as success and moderate and poor as failure.
|
From baseline (week 0) to end of study (up to 6 years and 10 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN7999-4404
- U1111-1198-6270 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.